BioCity’s SC0062 Met End Point for DKD in Phase 2 Trial

BioCity Biopharma announced that its drug SC0062 met the 12-week primary end point of a reduction in proteinuria in the diabetic kidney disease (DKD) cohort of the randomized, double-blind, placebo-controlled 2-SUCCEED phase 2 trial.

2-SUCCEED is designed to assess the efficacy and safety of SC0062, a selective endothelin receptor type A antagonist, in patients with chronic kidney disease with proteinuria. The study’s design includes 2 parallel cohorts, IgA nephropathy (IgAN) and DKD.

Most participants with DKD received sodium-glucose cotransporter-2 inhibitors and renin-angiotensin-aldosterone system inhibitors as background therapy. SC0062, both alone and in combination with these therapies, demonstrated outstanding efficacy and safety.

SC0062 significantly reduced proteinuria in patients with DKD in a high-dose group (20 mg) compared with a placebo group. Previously, SC0062 met all clinical end points in the IgAN cohort. A phase 3 trial for the treatment of IgAN, SUCCESS-01, is under way.

The 2-SUCCEED trial data, including the effects of SC0062 and placebo on proteinuria after 24 weeks of treatment, will be submitted to an upcoming scientific conference.

Source: Press release